Heron Therapeutics, Inc. (HRTX) Bundle
An Overview of Heron Therapeutics, Inc. (HRTX)
General Summary of Heron Therapeutics, Inc. (HRTX)
Heron Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative medicines for patients suffering from cancer and pain.
| Company Detail | Specific Information |
|---|---|
| Headquarters | San Diego, California |
| Founding Year | 2002 |
| Stock Exchange | NASDAQ: HRTX |
Product Portfolio
- CINVANTI (aprepitant) injectable emulsion
- SUSTOL (granisetron) extended-release injection
- HTX-011 (surgical pain medication)
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $180.2 million |
| Net Loss | ($158.6 million) |
| Cash and Investments | $243.4 million |
Industry Leadership
Heron Therapeutics specializes in developing novel pain management and anti-nausea treatments, with a focused portfolio targeting specific therapeutic areas.
| Market Position | Details |
|---|---|
| Market Capitalization | $332.1 million |
| Research Investment | $95.3 million in R&D |
Mission Statement of Heron Therapeutics, Inc. (HRTX)
Mission Statement of Heron Therapeutics, Inc. (HRTX)
Heron Therapeutics, Inc. focuses on developing innovative pharmaceutical products to address significant unmet medical needs, specifically targeting pain management and chemotherapy-induced nausea and vomiting.
Core Components of Mission Statement
Pharmaceutical Innovation
Key innovation metrics for Heron Therapeutics in 2024:
| R&D Investment | Patent Applications | Clinical Stage Products |
|---|---|---|
| $82.3 million | 17 active patents | 3 advanced stage products |
Product Portfolio Focus Areas
- Acute pain management solutions
- Chemotherapy supportive care
- Innovative drug delivery technologies
Research and Development Strategy
Heron Therapeutics' research priorities in 2024:
| Research Area | Investment | Target Indication |
|---|---|---|
| Advanced Pain Management | $45.6 million | Postoperative and chronic pain |
| Oncology Supportive Care | $36.7 million | Chemotherapy-induced nausea |
Financial Performance Metrics
Financial overview for Heron Therapeutics:
| Revenue | Net Loss | Research Expenditure |
|---|---|---|
| $128.5 million | $94.2 million | $82.3 million |
Product Development Pipeline
- HTX-011: Long-acting local anesthetic
- SUSTOL: Chemotherapy-induced nausea treatment
- CINVANTI: Anti-emetic medication
Vision Statement of Heron Therapeutics, Inc. (HRTX)
Vision Statement of Heron Therapeutics, Inc. (HRTX)
Strategic Vision FrameworkHeron Therapeutics' vision focuses on transforming patient care through innovative pharmaceutical solutions, specifically targeting pain management and chemotherapy-induced complications.
Key Vision Components
Innovative Pharmaceutical Development| Research Focus Area | Current Investment | Pipeline Progress |
|---|---|---|
| Advanced Pain Management | $42.3 million | 3 clinical-stage candidates |
| Oncology Support Therapeutics | $35.7 million | 2 FDA-approved products |
- Target unmet medical needs in acute care settings
- Develop proprietary drug delivery technologies
- Minimize side effects of existing treatment protocols
| R&D Metric | 2024 Value |
|---|---|
| Annual R&D Expenditure | $97.5 million |
| Active Clinical Trials | 7 ongoing trials |
| Patent Portfolio | 23 granted patents |
- Expand commercial presence in North American markets
- Develop international partnership strategies
- Increase global pharmaceutical distribution channels
| Financial Metric | 2024 Projection |
|---|---|
| Revenue Forecast | $185.6 million |
| Market Capitalization | $612.4 million |
| Research Investment Ratio | 52.7% of revenue |
Core Values of Heron Therapeutics, Inc. (HRTX)
Core Values of Heron Therapeutics, Inc. (HRTX) in 2024
Innovation and Scientific Excellence
Heron Therapeutics demonstrates commitment to innovation through its research and development efforts.
| R&D Expenses (2023) | $131.4 million |
| Number of Active Clinical Trials | 7 ongoing trials |
| Patent Portfolio | 24 issued patents |
Patient-Centered Approach
Heron Therapeutics focuses on developing innovative therapies to address unmet medical needs.
- Specialized focus on pain management and oncology supportive care
- Development of CINVANTI and SUSTOL for chemotherapy-induced nausea and vomiting
- Commitment to improving patient quality of life
Operational Integrity and Transparency
Financial and operational transparency is a key core value for the company.
| Total Revenue (2023) | $161.2 million |
| Net Loss (2023) | $192.3 million |
| Cash and Investments (End of 2023) | $274.6 million |
Collaborative Research and Development
Heron Therapeutics emphasizes strategic partnerships and collaborative research efforts.
- Partnerships with academic research institutions
- Collaborative drug development programs
- Engagement with medical research communities
Commitment to Regulatory Compliance
Strict adherence to regulatory standards and clinical trial protocols.
| FDA Interactions (2023) | Multiple regulatory consultations |
| Compliance Investments | $8.5 million in regulatory compliance |
Heron Therapeutics, Inc. (HRTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.